Watschinger B, Sayegh M H, Hancock W W, Russell M E
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Am J Pathol. 1995 May;146(5):1065-72.
Acute and chronic rejection are frequent and significant complications of cardiac transplantation, and graft arteriosclerosis is the leading cause of death beyond the first year after transplant. Levels of endothelin-1 (ET-1) are elevated in plasma of patients with cardiac allografts and those with symptomatic vascular atherosclerosis, but little is known about the role of ET-1 in these processes. This study examined intragraft ET-1 expression in rat cardiac models of acute rejection and chronic rejection associated with graft arteriosclerosis. Corrected ET-1 gene transcript levels were measured with a [32P]dCTP reverse transcription polymerase chain reaction assay normalized with glyceraldehyde-3-phosphate dehydrogenase, and the gene product was evaluated by immunohistology with a monospecific anti-ET-1 antibody at different time points after transplant. ET-1 mRNA levels were significantly increased in acutely rejected (Wistar-Furth rat cardiac allografts transplanted into Lewis rat recipients) and chronically rejected (Lewis allografts transplanted into F344 recipients) vascularized cardiac allografts as compared with isograft controls. In acutely rejected allografts, peak expression occurred on day 5 after transplant. In chronically rejected allografts, the increase in ET-1 mRNA was sustained on days 7, 28, and 75. In both acutely and chronically rejected allografts, ET-1 mRNA upregulation was not seen in host spleens or paired host hearts. Immunohistological analysis confirmed that the bulk of ET-1 peptide expression was localized to mononuclear cells that diffusely infiltrated the graft interstitium (acute rejection and early chronic rejection) and accumulated within the neointima of chronically rejecting hearts with arteriosclerosis. These observations, taken together with in vitro data showing that ET-1 production is stimulated by certain cytokines, indicate that the allogeneic stimulus within rejecting vascularized cardiac allografts, presumably cytokine mediated, leads to significant intragraft up-regulation of ET-1 mRNA and peptide expression. The local up-regulation of this vasoactive and mitogenic peptide within acutely and chronically rejected cardiac allografts suggests that ET-1 may be involved in the development of graft arteriosclerosis.
急性和慢性排斥反应是心脏移植常见且严重的并发症,移植血管硬化是移植后第一年以后的主要死亡原因。心脏同种异体移植患者和有症状性血管动脉粥样硬化患者的血浆中内皮素 -1(ET-1)水平升高,但ET-1在这些过程中的作用知之甚少。本研究检测了与移植血管硬化相关的急性排斥和慢性排斥大鼠心脏模型中移植物内ET-1的表达。用[32P]dCTP逆转录聚合酶链反应法并以甘油醛 -3-磷酸脱氢酶标准化来测定校正后的ET-1基因转录水平,并在移植后的不同时间点用单特异性抗ET-1抗体通过免疫组织学评估基因产物。与同基因移植对照组相比,在急性排斥(将Wistar-Furth大鼠心脏同种异体移植到Lewis大鼠受体)和慢性排斥(将Lewis同种异体移植到F344受体)的血管化心脏同种异体移植中,ET-1 mRNA水平显著升高。在急性排斥的同种异体移植中,移植后第5天出现峰值表达。在慢性排斥的同种异体移植中,ET-1 mRNA在第7、28和75天持续增加。在急性和慢性排斥的同种异体移植中,宿主脾脏或配对的宿主心脏中均未观察到ET-1 mRNA上调。免疫组织学分析证实,大部分ET-1肽表达定位于弥漫性浸润移植物间质的单核细胞(急性排斥和早期慢性排斥),并在伴有动脉硬化的慢性排斥心脏的新内膜内积聚。这些观察结果与体外数据表明某些细胞因子刺激ET-1产生一起,表明排斥的血管化心脏同种异体移植内的同种异体刺激(可能由细胞因子介导)导致移植物内ET-1 mRNA和肽表达显著上调。急性和慢性排斥的心脏同种异体移植中这种血管活性和促有丝分裂肽的局部上调表明ET-1可能参与移植血管硬化的发展。